^
Association details:
| Biomarker: | FGFR3 R248C |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | LY3076226 (Microtubule inhibitor, FGFR3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LY3076226, a novel anti-FGFR3 antibody drug conjugate exhibits potent and durable anti-tumor activity in tumor models harboring FGFR3 mutations or fusions
Excerpt:
LY3076226 was also efficacious after 4 weekly treatments at 5 mg/kg, resulting in tumor growth inhibition, tumor stasis or tumor regressions in bladder PDX models with G370C, S249C or R248C FGFR3 mutations, respectively.
DOI:
https://doi.org/10.1158/1538-7445.AM2019-4835
